Patents by Inventor Bernard J. Montagnon

Bernard J. Montagnon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Stabilizing vaccines
    Patent number: 5075110
    Abstract: A process for stabilizing attenuated lyophilized vaccines with a compound having the general formula: ##STR1## wherein R1 is an oxygen atom or a sulphur atom and R2 is a NH.sub.2 group or a linear chain, unsaturated or not, selected from the group consisting of --O--C . . . , --NH--C . . . , and --C . . . .
    Type: Grant
    Filed: June 21, 1989
    Date of Patent: December 24, 1991
    Assignee: Institut Merieux
    Inventors: Alain J. Francon, Bernard J. Montagnon
  • Process for the large scale production of rabies vaccine
    Patent number: 4664912
    Abstract: In the large-scale production of rabies vaccine a cell stock comprising a VERO cell strain and a liquid nutritive medium containing serum and microcarriers suspended therein is successively passed into biogenerators of increasing volume. The last of the passages is carried out in a biogenerator having a volume of at least 150 liters. The liquid nutritive medium is drawn off at the end of the final passage and replaced with a serum-free liquid nutritive medium. The cell stock is inoculated in the last passage biogenerator with virus which is allowed to develop. The virus is then cultured, withdrawn and filtered. The filtered liquid suspension is then ultrafiltered, with inactivated beta-propiolactone and purified by zonal centrifugation or chromatography.
    Type: Grant
    Filed: October 1, 1984
    Date of Patent: May 12, 1987
    Inventors: Tadeusz J. Wiktor, Bernard J. Fanget, Pierre Fournier, Bernard J. Montagnon
  • Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
    Patent number: 4525349
    Abstract: A process for large-scale production of poliomyelitis vaccine separately entails, for each type of poliomyelitis virus used, the following steps. A cell strain, using a cell stock, is multiplied by culturing the same in a liquid nutritive medium on microcarriers in suspension and by successive passages into biogenerator of increasing volumes. The last biogenerator is one having a capacity of at least 150 liters and the nutritive medium contains serum. This operation is carried out with stirring at a rate not greater than 40 rpm. At the end of the final passage the liquid nutritive medium is withdrawn and replaced by one that is serum-free. The biogenerator used for the last passage is then inoculated with virus which is permitted to develop, again with stirring at a rate not greater than 40 rpm. After virus culture, the liquid suspension is withdrawn, filtered, concentrated at least 150 times by ultrafiltration, subjected first to gel filtration and then to ion exchange chromatography.
    Type: Grant
    Filed: December 29, 1981
    Date of Patent: June 25, 1985
    Assignee: Societe Anonyme dite: Institut Merueux
    Inventors: Bernard J. Montagnon, Bernard J. C. Fanget